Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Feb 14, 2019 - Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Feb 12, 2019 - Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
Feb 11, 2019 - Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Feb 08, 2019 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.